SPRO — Spero Therapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has comple… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$2.93
Market Cap$161M
Float47.3M
Shares Outstanding57.9M
P/E (TTM)10.30
Price/Sales (TTM)2.63
vs. Analyst Target+36.5% to analyst PT
Profit Margin24.90%
Operating Margin (TTM)-2921.71%
Revenue (TTM)$61.2M
Earnings Growth (YoY)75.30%
Dividend RateNone
Analyst Target Price$4.00 (3 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $9.3M -$77.5M $9.3M -$78.4M
2021 $3.1M -$89.8M $3.1M -$87.2M
2022 $48.6M -$46.4M $48.6M -$42.9M
2023 $104M $22.8M $52.3M $27.2M
2024 $48.0M -$68.6M -$48.8M -$72.5M
2025 $59.6M $8.6M $59.6M -$24,000

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $11.8M -$1.7M
Sep 2025 $3.0M -$7.4M
Dec 2025 $39.7M $31.5M
Mar 2026 $258,000 -$7.2M

Ownership & Float

Insider Ownership22.5%
Institutional Ownership16.1%
Short Float2.5%
% of All Funds Holding0.55%
Number of Funds Holding45

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$2.64Near-term / short-term trend
Weekly40-Week SMA$2.37Medium-term trend
Weekly80-Week SMA$1.88Cyclical trend (business cycle)
Weekly200-Week SMA$1.64Secular trend (multi-year)
Monthly10-Month SMA$2.33Near-term monthly trend
Monthly20-Month SMA$1.87Medium-term monthly trend
Monthly40-Month SMA$1.66Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$2.60 support 1.25x 0 months ago
$0.70 support 8.51x 11 months ago

Historical Earnings Reactions (34 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -1.49% 0.03% 50.00% 6.06% -20.61%
1 Day -2.78% -2.04% 20.59% 13.11% -20.36%
1 Week -3.00% -2.10% 41.18% 21.18% -32.72%
2 Weeks 1.33% -4.43% 36.36% 208.70% -37.43%
1 Month 1.33% -5.59% 33.33% 313.04% -79.89%

Next earnings: August 1, 2026 (65 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan2.8%44.4%9
Feb-4.1%44.4%9
Mar0.2%44.4%9
Apr-2.3%33.3%9
May23.8%37.5%8
Jun0.6%50.0%8
Jul-6.2%25.0%8
Aug2.7%25.0%8
Sep14.1%37.5%8
Oct0.1%37.5%8
Nov1.8%50.0%8
Dec-1.2%33.3%9

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.02% 45.5% 402
Tuesday 0.19% 45.5% 444
Wednesday 0.48% 43.7% 439
Thursday 0.27% 45.9% 431
Friday -0.30% 44.3% 433

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 16.1%

Insider Transactions — Smart Summary

Total insider ownership: 22.5%

12-Month Insider Activity Summary

Total Filings8
Net Value-$762,871.044
Net Shares Change-16,291
% of Float-0.0%
C-Suite Filings7
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Rajavelu Esther Chief Executive Officer, Chief Financial Officer and Chief Business Officer -$614,337.7 4 1 sell
Keutzer Timothy Chief Operating Officer -$148,533.345 3 1 sell
Mahadevia Ankit -$12,946.84 1 1 sell

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-11-12 Rajavelu Esther Chief Executive Officer, Chief Financial Officer and Chief Business Officer -$95,439.9 Transaction at $2.37, now +23.6%
2025-09-02 Keutzer Timothy Chief Operating Officer -$3,339.15 Transaction at $1.97, now +48.7%
2025-09-02 Mahadevia Ankit -$12,946.84 Transaction at $1.97, now +48.7%
2026-02-09 Rajavelu Esther Chief Executive Officer, Chief Financial Officer and Chief Business Officer -$270,841.28 Transaction at $2.39, now +22.4%
2026-02-04 Rajavelu Esther Chief Executive Officer, Chief Financial Officer and Chief Business Officer -$40,572.4 Transaction at $2.20, now +33.2%
2026-02-09 Rajavelu Esther Chief Executive Officer, Chief Financial Officer and Chief Business Officer -$207,484.12 Transaction at $2.36, now +24.2%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Spero Therapeutics Inc (SPRO) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for SPRO on Trend Edge →